In the past few months the healthcare industry has sped up the adoption and implementation of digital remote healthcare solutions to meet patients’ health-related preferences and at the same time overcome the challenges of social distancing and limited human interaction. The pharmaceutical industry is also moving forward on the subject of virtual and hybrid clinical trials.
Join Link2Trials and EFPIA-IMI to improve patient adherence!
It is official now! A few weeks ago we have received confirmation from the EFPIA Innovative Medicine Initiative (IMI) that Link2Trials has been accepted as Associated Partner for the patient adherence improvement project (Call 23, Topic 6).
Patient non-adherence to prescribed treatment is an issue that affects patient health outcomes...
In most countries, regular care will be one of the first things to re-start post-Covid-19. With that, some of our clinical trials can re-start as well. We have discussed the re-start of trial recruitment with a lot of sites for a lot of studies in different countries and indications. This resulted in 4 pointers, for you to ensure the re-start of your trials and trial recruitment is as smooth as...
Today early drop-out still is a major challenge we must deal with when running clinical trials. The past few years patient centricity and patient engagement initiatives have generated major improvements. This is the second in a series of articles about a different perspective on the subject and a new and innovative approach to improve early drop-out rates.
Today early drop-out still is a major challenge we must deal with when running clinical trials. The past few years patient centricity and patient engagement initiatives have generated major improvements. This is the first in a series of articles about a different perspective on the subject and a new and innovative approach to improve early drop-out rates.
Early Drop-out; still a major...
A plea to express gratitude
Recently, I shared an editorial article from Nature on LinkedIn about the value and importance of true patient engagement in clinical trials. Involving patients from the earliest start of the clinical trial can and will lead to more effective and feasible clinical trial protocols. Patients are equivalent partners, and researchers need to incorporate patient feedback...
PreCare Trial & Recruitment wins the European Site Patient Recruitment Innovation Award (SPRIA EU) with a Link2Trials patient informed consent video
Last week at the 2018 Site Solutions Summit, PreCare Trial & Recruitment was awarded the SPRIA EU prize for their Informed Consent Form (ICF) video developed by Link2Trials. The video informed potential participants thoroughly about...
Growing costs of drug development
Over 95% of the clinical studies fail to meet their original time lines and budgets. Between 2006 and 2016 the global spending on drug development grew from $108 billion to over $148 billion. Clinical trials account for 45% to 75% of this cost and in 2012 the life sciences industry was already spending $1.2 billion on patient recruitment alone!
You ran a very successful online advertisement campaign for your clinical trial and you can see that many people have visited your clinical trial page. Unfortunately, very few follow through on their initial interest. Does this sound familiar to you? Then there is definitely something wrong with your online clinical trial information.
At first glance, your advertisement campaign seems to be in...
Online patient recruitment has proven to be a valuable strategy for finding the right subjects for the majority of the clinical trials. The very large online population accessible on the many social media platforms and the ability to specifically target the study population in the advertisement campaigns make online recruitment the tool of choice.
Join our next webinar and learn why social media...
According to a recent Microsoft report the average human attention span has dwindled from 12 seconds in 2000 to only 8 seconds in 2013. That is even less than a goldfish! These 8 seconds are very important because the average visitor of your website or portal will leave if he doesn’t find the information he is looking for in this very short timeframe.
It has already been mentioned in an...
The more I read about patient centricity, the more I get the eerie feeling that there is something wrong, something missing. At first glance the concept is very clear, the strategy and tactics are right and the tools put to use all have an added value. But it still doesn’t feel quite right to me. So what is it?
Being responsible for business development, I fully understand why the...
When reading about patient centricity one might get the impressions that technology will make it all happen. A lot of money is spent on portal solutions to make trial information more accessible for patients, and on mobile apps that will make it easier for patients to share the information the industry needs from them. But looking at these solutions the question pops to mind how all of this will...
According to data published by Zenithoptimedia, between 2010 and 2014 the average time people spent online grew from 60 to 110 minutes per day.
At the same time newspaper and magazine consumption dropped by 26% and 19%, respectively.
You will find more statistics at Statista
Moreover, according to a study by Reuters Institute for the Study of Journalism very few people consider print...
This year’s Clinical Trials Innovation Program (CTIP) will be held in Frankfurt on 22-23 October 2015.
The CTIP is an exclusive, invitation only event and each year helps senior executives from Pharma & Biotech industries to forge strong and lasting business relationships and to share best practice and knowledge about the very latest issues affecting the industry.
The event will...
Recently the National Cancer Institute in the US has published a concise and easy to read step-by-step guide for cancer patients who are looking for clinical trials. Each of the ten steps in the guide explains in simple terms what to do and if applicable where to find more detailed information.
The guide not only provides links to multiple sources containing information about ongoing and...
The roundtable discussion we facilitated in London last month, made us aware that there still is a lot of misunderstanding and concerns in the pharmaceutical industry about using social media as an effective tool for patient recruitment and patient centricity.
We also learned that there is a lot of interest for informal and interactive discussions with peers about this particular subject,...
At last month’s Proventa 2015 Clinical Data Strategy Meeting in London, Link2Trials’ Managing Director Simon Klaasen facilitated a successful round-table discussion about the pros and cons of using social media for patient recruitment and how it can boost patient centricity.
Twenty delegates from 15 different pharmaceutical companies attended the round-table and during a lively...
It seems that nowadays patient centricity is a hot topic for everyone in the life science industry. Many articles are written about patient centricity, and more and more events and conferences use it as the main subject. But will the industry feel the same way about patient centricity a few years from now, or will it be discarded as just a lot of hot air?
We believe it is not and that it is the...
On July 1, 2015 Link2Trials will attend the Clinical Data Strategy Meeting Europe 2015 in London.
Simon Klaasen will facilitate a roundtable discussion about patient centricity, social media and patient recruitment based on the following statements:
Patient centricity, engagement and empowerment will increase patient participation in clinical trials
Social media can be a very efficient tool...
Reasons for Change
It has all been said before: Over 95% of the clinical studies fail to meet their original time lines and budgets and that one day of delay could cost a sponsor $1.6 million on averaged lost revenue.
Between 2006 and 2016 the global spending on drug development will grow from $108 billion to over $148 billion. Clinical trials account for 45% to 75% of this cost and...